|Day Low/High||16.95 / 18.75|
|52 Wk Low/High||8.38 / 20.00|
Summit Therapeutics and Epizyme are raising cash to fund new drug development.
GlaxoSmithKline could be among the suitors for United Therapeutics, the Evening Standard reported.
Eligible Patients to be Directed to Epizyme's Ongoing Phase 2 Clinical Trial of Tazemetostat in Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Sangamo Therapeutics, Epizyme and Revance were among the biotech stock movers in premarket trading on June 21.
Investors in Epizyme Inc. saw new options begin trading this week, for the February 2018 expiration.
AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20.
Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat
Epizyme, Alexion Pharmaceuticals and XBiotech were among the biotech stock movers premarket trading on June 14.
Investors in Epizyme Inc. saw new options become available this week, for the July 21st expiration.
Management to Host Conference Call on May 18, 2017 at 8:30 a.m. ET
Dr. Copeland to Remain a Key Advisor to Epizyme Following Transition
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.